Elafibranor for the treatment of patients with primary biliary cholangitis

14 November 2024 - NICE has published final evidence-based recommendations on the use of elafibranor (Iqirvo) for the treatment of ...

Read more →

Teclistamab for the treatment of patients with relapsed and refractory multiple myeloma after three or more treatments (final guidance)

13 November 2024 - NICE has published final evidence-based recommendations on the use of teclistamab (Tecvayli) for the treatment of ...

Read more →

Sanofi wins appeal in spat with NICE over Sarclisa

13 November 2024 - Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS ...

Read more →

Alectinib hydrochloride for the adjuvant treatment of patients with ALK positive non-small-cell lung cancer

13 November 2024 - NICE has published final evidence-based recommendations on the use of alectinib hydrochloride for the adjuvant treatment ...

Read more →

Avapritinib for the treatment of patients with advanced systemic mastocytosis

6 November 2024 - NICE has published evidence-based recommendations on the use of avapritinib (Ayvakyt) for the treatment of adults ...

Read more →

Fenfluramine hydrochloride for the treatment of patients 2 years of age and older with seizures associated with Lennox–Gastaut syndrome

5 November 2024 - Following an appeal, NICE has published further draft guidance on the use of using fenfluramine hydrochloride ...

Read more →

Leniolisib phosphate for the treatment of patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome

31 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Osimertinib mesylate in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with advanced EGFR mutation positive non-small-cell lung cancer

30 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy

29 October 2024 - Hundreds of people with a rare form of blood cancer could be set to benefit after NICE ...

Read more →

Driving down the cost of biologics: lessons from a nationalised health care system

18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...

Read more →

Quizartinib dihydrochloride for the induction, consolidation and maintenance treatment of adults with newly diagnosed FLT3-ITD positive acute myeloid leukaemia

23 October 2024 - NICE has published final evidence-based recommendations on the use of quizartinib dihydrochloride (Vanflyta) for the induction, ...

Read more →

New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE

23 October 2024 - More evidence is needed on the clinical and cost effectiveness of donanemab, a new treatment for mild ...

Read more →

Danicopan in combination with ravulizumab or eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (final guidance)

23 October 2024 - NICE has published final evidence-based recommendations on the use of danicopan (Voydeya) in combination with ravulizumab ...

Read more →

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE

17 October 2024 - For the first time, NICE has recommended a targeted treatment option for ALK positive non-small-cell lung cancer, ...

Read more →

Fruquintinib for patients with previously treated metastatic colorectal cancer

8 October 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →